WASHINGTON, March 4, 2026, 07:18 EST
- The FDA flagged Ozempic for a consumer ad it says made false or misleading statements, suggesting the drug was better than other GLP-1s.
- Novo Nordisk says it’s responding after regulators flagged its advertising for a second time in less than a month.
- The move follows increased FDA scrutiny on GLP-1 marketing, with telehealth companies promoting compounded versions also under the microscope.
Novo Nordisk A/S received a notice from the U.S. Food and Drug Administration regarding a consumer advertisement for its diabetes blockbuster, Ozempic. The FDA says the commercial makes claims about the drug’s benefits that are false and misleading. This marks the second warning in under a month for the Danish drugmaker’s advertising practices. Reuters
This shift hits Novo where it counts: Ozempic and its sibling Wegovy are pivotal for the company’s U.S. expansion, with marketing playing a key role in carving out space amid heavy competition. Tweaking the message under pressure risks confusing patients and physicians, who are already navigating complicated choices.
The move comes as the FDA sharpens its stance on prescription drug marketing, following a directive from U.S. President Donald Trump to increase scrutiny over how companies pitch their medicines. That’s left drugmakers facing a higher risk that bold comparisons or sweeping statements could get flagged more quickly.
The regulator, in a letter dated Feb. 26, accused Novo of misrepresenting what Ozempic is approved to treat in an online advertisement and suggested the company implied Ozempic topped other GLP‑1 therapies for type 2 diabetes. GLP‑1 drugs act like the gut hormone glucagon-like peptide‑1, used to help regulate blood sugar and sometimes curb appetite.
The FDA flagged the commercial for implying that every type 2 diabetes patient could use Ozempic for all its approved uses, despite some indications being limited to those with heart disease or chronic kidney issues. The agency also criticized the ad’s humor—specifically a bit where Ozempic was compared to other GLP-1 drugs—saying it suggested rivals offered little value.
The agency instructed Novo to reply in writing within 15 working days of receiving the letter, identify any other similar ads, and describe how it plans to pull them—or else stop distributing Ozempic entirely.
Novo is addressing concerns from regulators. “We take all regulatory feedback seriously and are in the process of responding to the FDA,” spokesperson Liz Skrbkova said. She confirmed the company had received an “untitled letter,” the FDA’s term for a notice that highlights alleged promotional violations.
According to the regulator, the Ozempic notice comes after a different FDA letter from Feb. 5 that raised concerns about a TV commercial for Novo’s obesity drug Wegovy.
The FDA on Tuesday sent warning letters to 30 telehealth companies accused of promoting compounded GLP‑1 drugs, which are custom-mixed by pharmacies. “It’s a new era of enforcement,” said FDA Commissioner Marty Makary, cautioning firms not to market compounded drugs as stand-ins for approved treatments. Reuters
The FDA said its letters to telehealth providers centered on compounded semaglutide — that’s the active component in Ozempic and Wegovy — along with tirzepatide, found in Eli Lilly’s Zepbound and Mounjaro.
An FDA “untitled letter” usually flags issues a company needs to fix, but stops short of the more serious “warning letter” and skips the explicit threat of enforcement action. The agency makes clear it isn’t required by law to provide any advance notice before moving ahead with enforcement, so firms can’t count on delays. U.S. Food and Drug Administration
